Attovia Therapeutics

ATTO · NASDAQ

$13.83−$0.67 (−4.62%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $14.50

ATTO analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $43.04 (+211.2% upside)

Low: $30.30
Now: $13.83
High: $54.60

Upgrades and downgrades

The latest rating actions, newest first

ATTO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Aug 31, 2026	Initiates	Buy	$30.00	43%
LifeSci Capital	Aug 31, 2026	Initiates	Outperform	$45.00	—
Leerink Partners	Aug 31, 2026	Initiates	Outperform	$52.00	25%
RBC Capital	Aug 31, 2026	Initiates	Outperform	$45.00	44%
Morgan Stanley	Aug 31, 2026	Initiates	Overweight	$39.00	57%

The case for and against

Updated Oct 22, 2026

Bull case

Attovia Therapeutics is supported by a de-risked IL-31 thesis, with Nemluvio’s clinical success and $1B early run-rate validating the itch-market opportunity while ATTO-1310’s week 4 efficacy, biparatopic binding, and YTE half-life extension suggest a potentially stronger, quarterly-dosed profile. Its ATTOBODY platform adds strategic value by enabling optimized mono- and multispecific biologics, and preclinical signals from ATTO-2306 and ATTO-1091 indicate durable effects, low immunogenicity, and differentiated multi-target mechanisms in large immune-inflammatory markets. With a $2.7B+ worldwide peak sales opportunity for ATTO-1310, $2B+ potential for ATTO-2306, and a trispecific IBD program that targets TL1A, IL-23, and α4β7, the pipeline offers multiple shots on goal that could drive meaningful long-term upside.

Bear case

Attovia Therapeutics is a clinical-stage biotech with no revenues, so its valuation depends entirely on unproven assets and repeated financing, creating substantial dilution and execution risk. Its lead programs ATTO-1310, ATTO-2306, and ATTO-1091 still must clear efficacy, safety, manufacturing, and regulatory hurdles, while even its own data show only modest clinical signals, such as 38%/34% PP-NRS improvement and 19.2% WI-NRS improvement in CKD-aP, with Galderma deprioritizing that indication. The commercial backdrop is also challenging because the addressable markets are crowded in immune-dermatology and IBD, competitors may offer more established or differentiated therapies, and the company could struggle to fund ongoing R&D if development timelines slip.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.